Skip to main content Accessibility help

Should We Routinely Use Mupirocin to Prevent Staphylococcal Infections?

  • Virginia R. Roth (a1) (a2), Cathryn Murphy (a3), Trish M. Perl (a4), Alfred DeMaria (a4), Annette H. Sohn (a1), Ronda L. Sinkowitz-Cochran (a1) and William R. Jarvis (a1)...


Routine use of mupirocin to prevent staphylococcal infections is controversial. We assessed attitudes and practices of healthcare professionals attending the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections regarding mupirocin prophylaxis. Eighty percent of participants did not use mupirocin routinely. At the end of the session, 58% indicated they would consider increased use of mupirocin.


Corresponding author

Division of Infectious Diseases, The Ottawa Hospital, 501 Smyth Rd, Room G-12, Ottawa, Ontario K1H8L6, Canada


Hide All
1.Chow, JW, Yu, VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989;149:12581262.
2.Herwaldt, LA. Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients./Hosp Infect 1998;40(suppl B):S13S23.
3.Kluytmans, J, van Belkum, A, Verbrugh, H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505520.
4.Bloom, BS, Fendrick, AM, Chernew, ME, Patel, P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis Patients a decision analysis. Am J Kidney Dis 1996;27:687694.
5.National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance System (NNIS) System. Am J Infect Control 1996;24:380388.
6.Rubin, RJ, Harrington, CA, Poon, A, Dietrich, K, Greene, JA, Moiduddin, A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999;5:917.
7.Fridkin, SK, Gaynes, RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303316.
8.Smith, TL, Pearson, ML, Wilcox, KR, Cruz, C, Lancaster, MV, Robinson-Dunn, B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. NEngl f Med 1999;340:493501.
9.Sohn, AH, Sinkowitz-Cochran, RL, Jarvis, WR. Program Overview, The Reality Check Sessions at the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Infect Control Hosp Epidemiol 2000;21:742744.
10.Perl, TM, Golub, JE. New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S aureus nasal carriage. Ann Pharmacother 1998;32(suppl):S7S16.
11.Wenzel, RP, Perl, TM. The significance of nasal carriage oi Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:1324.
12.Boyce, JM. Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 1996;17:775779.
13.Brown, P, Davies, DT, O'Hanlon, PJ, Wilson, JM. The chemistry of Pseudomonic acid, 15: synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles. J Med Chem 1996;39:446457.
14.Perl, TM, Cullen, JJ, Pfaller, MA, Wenzel, RP, Zimmerman, B, Herwaldt, LAet al. A randomized, double-blind, placebo-controlled clinical trial of intranasal mupirocin to prevent S aureus nosocomial infections. Infect Control Hosp Epidemiol 1999;20:282. Abstract 45.
15.Kluytmans, J. Reduction of surgical site infections in major surgery by elimination of nasal carriage of Staphylococcus aureus. J Hosp Infect 1998;40(suppl B):S25S29.
16.Doebbeling, BN, Breneman, DL, Neu, HC, Aly, RYangco, BG, Holley, HP Jr, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993;17:466474.
17.Boelaert, JR. Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994;6(suppl 2):S19S24.
18.Henkel, T, Finlay, J. Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J Chemother 1999;11:331337.
19.Miller, MA, Dascal, A, Portnoy, J, Mendelson, J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811813.

Should We Routinely Use Mupirocin to Prevent Staphylococcal Infections?

  • Virginia R. Roth (a1) (a2), Cathryn Murphy (a3), Trish M. Perl (a4), Alfred DeMaria (a4), Annette H. Sohn (a1), Ronda L. Sinkowitz-Cochran (a1) and William R. Jarvis (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed